Literature DB >> 24937690

Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy.

Tiphaine Vaché1, Flavie Bratan, Florence Mège-Lechevallier, Sylvain Roche, Muriel Rabilloud, Olivier Rouvière.   

Abstract

PURPOSE: To compare the subjective Likert score to the Prostate Imaging Reporting and Data System (PIRADS) and morphology-location-signal intensity (MLS) scores for categorization of prostate lesions as benign or malignant at multiparametric magnetic resonance (MR) imaging.
MATERIALS AND METHODS: Two hundred fifteen patients who underwent T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced multiparametric MR imaging of the prostate before radical prostatectomy were included in a prospective database after they signed the institutional review board-approved forms. Senior readers 1 and 2 prospectively noted the location, shape, and signal intensity of lesions on MR images from individual pulse sequences and scored each for likelihood of malignancy by using a Likert scale (range, 1-5). A junior reader (reader 3) retrospectively reviewed the database and did the same analysis. The MLS score (range, 1-13) was computed by using the readers' descriptions of the lesions. Then, the three readers again scored the lesions they described by using the PIRADS score (range, 3-15). MLS and PIRADS scores were compared with the Likert score by using their areas under the receiver operating characteristic curves.
RESULTS: Areas under the receiver operating characteristic curves of the Likert, MLS, and PIRADS scores were 0.81, 0.77 (P = .03), and 0.75 (P = .01) for reader 1; 0.88, 0.74 (P < .0001), and 0.76 (P < .0001) for reader 2; and 0.81, 0.78 (P = .23), and 0.75 (P = .01) for reader 3. For diagnosing cancers with Gleason scores greater than or equal to 7, the Likert score was significantly more accurate than the others, except for the MLS score for reader 3. Weighted κ values were 0.470-0.524, 0.405-0.430, and 0.378-0.441 for the Likert, MLS, and PIRADS scores, respectively.
CONCLUSION: The Likert score allowed significantly more accurate categorization of prostate lesions on MR images than did the MLS and PIRADS scores.

Entities:  

Mesh:

Year:  2014        PMID: 24937690     DOI: 10.1148/radiol.14131584

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  34 in total

1.  Multiparametric MRI of the prostate at 3 T: limited value of 3D (1)H-MR spectroscopy as a fourth parameter.

Authors:  Stephan H Polanec; Katja Pinker-Domenig; Peter Brader; Dietmar Georg; Shahrokh Shariat; Claudio Spick; Martin Susani; Thomas H Helbich; Pascal A Baltzer
Journal:  World J Urol       Date:  2015-09-25       Impact factor: 4.226

2.  A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).

Authors:  Sonia Gaur; Stephanie Harmon; Rajan T Gupta; Daniel J Margolis; Nathan Lay; Sherif Mehralivand; Maria J Merino; Bradford J Wood; Peter A Pinto; Joanna H Shih; Peter L Choyke; Baris Turkbey
Journal:  Acad Radiol       Date:  2018-04-25       Impact factor: 3.173

3.  Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Authors:  Mrishta Brizmohun Appayya; Harbir S Sidhu; Nikolaos Dikaios; Edward W Johnston; Lucy Am Simmons; Alex Freeman; Alexander Ps Kirkham; Hashim U Ahmed; Shonit Punwani
Journal:  Br J Radiol       Date:  2017-12-15       Impact factor: 3.039

4.  PIRADS 2.0: what is new?

Authors:  Baris Turkbey; Peter L Choyke
Journal:  Diagn Interv Radiol       Date:  2015 Sep-Oct       Impact factor: 2.630

Review 5.  A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer.

Authors:  Li Zhang; Min Tang; Sipan Chen; Xiaoyan Lei; Xiaoling Zhang; Yi Huan
Journal:  Eur Radiol       Date:  2017-06-27       Impact factor: 5.315

6.  The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.

Authors:  Pedro Recabal; Melissa Assel; Daniel D Sjoberg; Daniel Lee; Vincent P Laudone; Karim Touijer; James A Eastham; Hebert A Vargas; Jonathan Coleman; Behfar Ehdaie
Journal:  J Urol       Date:  2016-02-23       Impact factor: 7.450

7.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.

Authors:  Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis
Journal:  Radiology       Date:  2016-04-01       Impact factor: 11.105

8.  Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.

Authors:  H A Vargas; A M Hötker; D A Goldman; C S Moskowitz; T Gondo; K Matsumoto; B Ehdaie; S Woo; S W Fine; V E Reuter; E Sala; H Hricak
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

9.  Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2.

Authors:  Matthew D Greer; Joanna H Shih; Nathan Lay; Tristan Barrett; Leonardo Kayat Bittencourt; Samuel Borofsky; Ismail M Kabakus; Yan Mee Law; Jamie Marko; Haytham Shebel; Francesca V Mertan; Maria J Merino; Bradford J Wood; Peter A Pinto; Ronald M Summers; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2017-07-19       Impact factor: 11.105

10.  Usage of structured reporting in radiological practice: results from an Italian online survey.

Authors:  Lorenzo Faggioni; Francesca Coppola; Riccardo Ferrari; Emanuele Neri; Daniele Regge
Journal:  Eur Radiol       Date:  2016-08-29       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.